trending Market Intelligence /marketintelligence/en/news-insights/trending/ymafn6ieuovumwmxyrwkkq2 content esgSubNav
In This List

Pfizer skin disease drug bags US FDA breakthrough therapy designation

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Pfizer skin disease drug bags US FDA breakthrough therapy designation

Pfizer Inc. received the U.S. Food and Drug Administration's breakthrough therapy designation for PF-04965842 to treat a skin disease.

The drug is being developed as a treatment of moderate to severe atopic dermatitis, a chronic inflammatory disease that makes the skin red and itchy.

The designation will help expedite development and review of the drug which targets the Janus kinase, or JAK, family of enzymes in the body.

The U.S. regulator previously awarded the same designation to AbbVie Inc.'s ABT-494, or upadacitinib, another JAK inhibitor being investigated as a treatment for moderate to severe atopic dermatitis.